Table 2.
Correlation between inflammation-based markers and clinicopathological characteristics of LSCC patients
| Characteristics | AGR | NLR | PLR | LMR | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (years) | <1.31 n=119 | ≥1.31 n=113 | P | <2.38 n=48 | ≥2.38 n=184 | P | <116 n=130 | ≥116 n=102 | P | <2.01 n=70 | ≥ 2.01 n=162 | P | |||
| <60 | 54(45.4%) | 59(52.2%) | 0.301 | 24(50.0%) | 89(48.4%) | 0.832 | 59(43.4%) | 54(52.9%) | 0.247 | 36(51.4%) | 77(47.5%) | 0.589 | |||
| ≥60 | 65(54.6%) | 54(47.8%) | 24(50.0%) | 95(51.6%) | 71(54.6%) | 48(47.1%) | 34(48.6%) | 85(52.5%) | |||||||
| Gender | |||||||||||||||
| Male | 98(82.4%) | 94(83.2%) | 0.859 | 40(83.3%) | 152(82.6%) | 0.908 | 107(82.3%) | 85(83.3%) | 0.836 | 59(84.3%) | 133(82.1%) | 0.681 | |||
| Female | 21(17.6%) | 19(16.8%) | 8(16.7%) | 32(17.4%) | 23(17.7%) | 17(16.7%) | 11(15.7%) | 29(17.9%) | |||||||
| Smoking history | |||||||||||||||
| No | 44(37.0%) | 55(48.7%) | 0.156 | 25(52.1%) | 74(40.2%) | 0.134 | 58(44.6%) | 41(40.2%) | 0.488 | 33(47.1%) | 66(40.7%) | 0.821 | |||
| Yes | 75(63.0%) | 58(51.3%) | 23(47.9%) | 110(59.8%) | 72(55.4%) | 61(59.8%) | 37(52.9%) | 96(59.3%) | |||||||
| Drinking history | |||||||||||||||
| No | 70(58.8%) | 71(63.4%) | 0.481 | 31(64.6%) | 110(59.8%) | 0.542 | 83(63.8%) | 58(56.9%) | 0.278 | 36(51.4%) | 105(64.8%) | 0.064 | |||
| Yes | 49(41.2%) | 41(36.6%) | 17(35.4%) | 74(40.2%) | 47(36.2%) | 44(43.1%) | 34(48.6%) | 57(35.2%) | |||||||
| Tumor site | |||||||||||||||
| Supraglottic | 46(38.7%) | 28(24.8%) | 0.018* | 11(22.9%) | 57(31.0%) | 0.268 | 37(28.5%) | 31(30.4%) | 0.751 | 20(28.6%) | 48(29.6%) | 0.874 | |||
| Glottic&Subglottic | 73(61.3%) | 85(75.2%) | 37(77.1%) | 127(69.0%) | 93(71.5%) | 71(69.6%) | 50(71.4%) | 114(70.4%) | |||||||
| Tumor size | <0.001* | ||||||||||||||
| ≤2cm | 51(42.9%) | 69(61.1%) | 32(66.7%) | 88(47.8%) | 0.022* | 76(58.5%) | 44(43.1%) | 0.016* | 28(40.0%) | 92(56.8%) | 0.007* | ||||
| >2cm | 68(57.1%) | 44(38.9%) | 16(33.3%) | 96(52.2%) | 54(41.5%) | 58(56.9%) | 42(60.0%) | 70(43.2%) | |||||||
| T Stage | |||||||||||||||
| T1+2 | 58(48.7%) | 83(73.5%) | <0.001* | 37(77.1%) | 104(56.5%) | <0.001* | 88(67.7%) | 53(52.0%) | 0.011* | 33(47.1%) | 108(66.7%) | <0.001* | |||
| T3+4 | 61(51.3%) | 30(26.5%) | 11(22.9%) | 80(43.5%) | 42(32.3%) | 49(48.0%) | 37(52.9%) | 54(33.3%) | |||||||
| Lymph node metastasis | <0.001* | ||||||||||||||
| N0 | 46(38.7%) | 74(65.5%) | 32(66.7%) | 88(47.8%) | 0.021* | 70(53.8%) | 50(49.0%) | 0.471 | 15(21.4%) | 105(64.8%) | <0.001* | ||||
| N+ | 73(61.3%) | 39(34.5%) | 16(33.3%) | 96(52.2%) | 60(46.2%) | 52(51.0%) | 55(78.6%) | 57(35.2%) | |||||||
| TNM stage | <0.001* | 0.017* | 0.019* | 0.011* | |||||||||||
| I+II | 42(35.3%) | 77(68.1%) | 32(66.7%) | 87(47.3%) | 75(57.7%) | 44(43.1%) | 27(38.6%) | 92(56.8%) | |||||||
| III-IV | 77(64.7%) | 36(31.9%) | 16(33.3%) | 97(52.7%) | 55(42.3%) | 58(56.9%) | 43(61.4%) | 70(43.2%) | |||||||
| Differentiation grade | 0.483 | 0.402 | 0.168 | 0.387 | |||||||||||
| Poor | 18(15.1%) | 21(18.6%) | 10(20.8%) | 29(15.8%) | 18(13.8%) | 21(20.6%) | 14(20.0%) | 25(15.4%) | |||||||
| Moderate & Well | 101(84.9%) | 92(81.4%) | 38(79.2%) | 155(84.2%) | 112(86.2%) | 81(79.4%) | 56(80.0%) | 137(84.6%) | |||||||
Abbreviations: HR hazard ratio, 95% CI 95% confidencel interval, AGR albumin/globulin ratio
NLR neutrophil/lymphocyte ratio, PLR platelet/lymphocyte ratio, LMR lymphocyte/monocyte ratio, LSCC laryngeal squamous cell carcinoma
* P < 0.05 considered as statistically significant.